Cargando…
Metabolic Reprogramming During Multidrug Resistance in Leukemias
Cancer outcome has improved since introduction of target therapy. However, treatment success is still impaired by the same drug resistance mechanism of classical chemotherapy, known as multidrug resistance (MDR) phenotype. This phenotype promotes resistance to drugs with different structures and mec...
Autores principales: | Vidal, Raphael Silveira, Quarti, Julia, Rumjanek, Franklin D., Rumjanek, Vivian M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895924/ https://www.ncbi.nlm.nih.gov/pubmed/29675398 http://dx.doi.org/10.3389/fonc.2018.00090 |
Ejemplares similares
-
Corrigendum: Metabolic Reprogramming During Multidrug Resistance in Leukemias
por: Vidal, Raphael Silveira, et al.
Publicado: (2018) -
Selective Cytotoxicity of Piperine over Multidrug Resistance Leukemic Cells
por: Quarti, Julia, et al.
Publicado: (2021) -
Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR–CML cell lines?
por: Rumjanek, Vivian M., et al.
Publicado: (2013) -
Detachment of Hexokinase II From Mitochondria Promotes Collateral Sensitivity in Multidrug Resistant Chronic Myeloid Leukemia Cells
por: Oliveira, Thaís, et al.
Publicado: (2022) -
Osmolyte Induced Tumorigenesis and Metastasis: Interactions With Intrinsically Disordered Proteins
por: Rumjanek, Franklin D.
Publicado: (2018)